Remyelination is critical for white matter stroke recovery

Yaning Li

Neurosurgery Department, School of Medicine, Stanford University, CA, US

Abstract: Stroke is a major cause of worldwide death and disability. Numerous events are triggered in the brain after stroke onset, which together lead to irreversible non-selective brain cells death, including neurons, endothelial cells, oligodendrocytes etc. The only sufficient clinical treatment, recombination tissue plasminogen activator (tPA), limits its administration in patients due to its very narrow treatment window and the risk of hemorrhage. Many studies have been carried out to find new therapeutic treatments, which are generally categorized into drugs/chemokine/cytokine treatment, stem cell therapy, gene therapy, stem cell-based gene therapy and other physical therapy. These studies are mainly focused on reduction of inflammatory response, protection of blood-brain barrier (BBB) integrity, and promotion of angiogenesis and neurogenesis. After stroke, white matter is more vulnerable to deprivation of glucose and oxygen. A very vital component of whiter matter is oligodendrocytes, which ensheath the axons to form myelin and ensure proper pulse signal transduction. However, the studies on how to protect the integrity of white matter myelin, and promote the remyelination after stroke are much fewer than those for angiogenesis and neurogenesis. Angiogenesis, neurogenesis, and remyelination are indispensable for neurobehavioral function recovery after stroke. The therapeutic treatments for remyelination should be treated as important as those for angiogenesis and neurogenesis during stroke recovery phase.

Key words: Stroke; treatment; remyelination; white matter.

Stroke

Stroke is a leading cause of worldwide human death and disability (1, 2). It includes two types of stroke, is-chemic stroke and hemorrhagic stroke. Ischemic stroke is induced by blood vessel occlusion with > 70% stroke incidence, while hemorrhagic stroke is induced by blood vessel rupture. After stroke, the brain is deprived of oxy-gen and glucose, which is vital for the neurons mainte-nance (3). The neurons will die from its vulnerability to stroke within minutes. Neurological deficits usually occur accompanying with the death of neurons after stroke onset (4). The only food and drug administration (FDA) appro-ved clinical treatment is recombinant tissue plasminogen activator (rtPA) thrombolysis (5). rtPA is administrated intravenously in ischemic stroke patients for thromboly-sis by breakdown of blood clots. However, very limited patients are timely treated with tPA due to its very narrow treatment window, only within 4.5 hours after stroke onset (6). Stoke triggers a process of pathophysiological events in brain, including energy failure, iron dyshomeostasis, in-flammatory cytokines release, blood-brain barrier (BBB) disruption, immune response activation etc (7, 8). These events interrelate, coordinate and finally result in non-se-lective cell deaths, including neurons, astrocytes, oligo-dendrocytes, endothelial cells etc. The brain will continue deteriorating for several days, even months (9, 10). The early diagnosis is more important than post-stroke recove-ry treatment, but no very efficient tools for the clinicians to perform on the clinical patients. Near real time single-pair fluorescence resonance transfer analysis of mRNA transcripts for stroke-related gene expression may assist clinicians to treat patients with appropriate time-sensitive therapeutics (11, 12).

Recent treatments for stroke

A numerous preclinical experiments have been tried to ameliorate brain injury or to promote angiogenesis and neurogenesis in stroke injured brain. These thera-peutic treatments can mainly be categorized into drugs/ chemokine/cytokine therapy, stem cell therapy, gene the-rapy, stem cell-based gene therapy and other physical therapy. Drugs can reduce brain inflammation, protect BBB integrity, increase stem cells homing etc. For exa-mple, metformin, a widely used hypoglycemic drug, has been showed to protect brain injury, reduce inflammatory cells infiltration, and protect BBB integrity in ischemic mice (13). AMD3100, a well recognized antagonist of CXCR4 and widely applied to block CXCL12/CXCR4 signaling, has been demonstrated to suppress inflamma-tory response and reduce BBB permeability in ischemic mice (14). Granulocyte-macrophage colony-stimulating factor (GM-CSF), a hematopoietic cytokine, is demons-trated to act as a neuroprotective protein in central ner-vous system (CNS) (15). Besides, erythropoietin (EPO) (16), granulocyte colony-stimulating factor (G-CSF) (17) etc are considered as clinical candidates for their endoge-nous neuroprotective roles in stroke. Many other drugs/ chemokine/cytokines are administrated to stroke ani-mals, and also have been showed that they can promote angiogenesis and/or neurogenesis, such as interleukin-10 (IL-10) (18), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) (19), in-

sulin growth factor-1 (IGF-1) (20), fluoxetine (21), in-ducible nitric oxide synthase (iNOS) (22) etc. Stem cells including embryonic stem cells (ESCs) (23), mesenchy-mal stem cells (MSCs) (24, 25), endothelial progenitor cells (EPCs) (26-28), neural stem cells (NSCs) (29, 30), vascular progenitor cells (VPCs) (31) have been showed that their transplantation into stroke animals ameliorated brain injury, either by releasing neurotrophic factors to protect brain or by cell integration into the injury site for cell replacement. A large number of genes has been se-lected for gene therapy of stroke, which include insulin growth factor-1 (IGF-1) (32), BDNF (33), stromal derived factor-1 (SDF-1, also named as CXCL12) (34), epider-mal growth factor (EGF) (35), glial cell line-derived neu-rotrophic factor (GDNF) (36), hepatocyte growth factor (HGF) (37), hypoxia induced factor-1 (HIF-1) (38) etc. To some extent, these genes therapeutic treatments for stroke improved animals' behavioral function by either protecting brain against stroke injury or promoting brain recovery via enhancing angiogenesis and/or neurogenesis. Gene modified stem cells are aimed to enhance the cell function and viability. Many kinds of modified stem cells have been used to treatment of stroke. MSCs have been modified by BNDF (39), GDNF (40), HGF (37), placen-ta growth factor (PIGF) (41), VEGF (42), angiopoietin-1 (43, 44), CXCR4 (45) genes. NSCs were showed success-fully modified by VEGF (46), neurotrophin-3 (47, 48), GDNF (49), BDNF (50), Akt-1 (51) genes. EPCs can be modified by VEGF (52), SDF-1/CXCL12 (53) etc. These gene modified stem cells are commonly showed their bet-ter beneficial effect on stroke recovery than stem cell treat-ments alone, but mainly focusing on promoting angioge-nesis and/or neurogenesis. Besides these treatments, there are some other physical treatments to help patients to gain motor functions, such as acupuncture, electroacupuncture etc (54-56).

Stroke induced-white matter injury is vital for stroke recovery

Not only more than 25% ischemic strokes in humans happens in subcortical, but cortical infarcts also damage white matter (57). The white matter is composed main-ly of axons and glial cells, but lacking of neuronal cell bodies or their dendrites. Besides blood vessel injury and neurons death, there is an important injury in brain white matter is myelin degradation, named as demyelina-tion. Myelin wraps the axons to ensure fast nerve impulse conduction and is vital for maintenance of the axon cy-toskeleton (58-61). Myelin is composed of mature oligo-dendrocytes. Because of the little collateral blood supply in the white matter, where the myelin is rich, the white matter is more vulnerable than gray matter to stroke at-tack (62-64). Oligodendrocyte progenitor cells (OPCs) harbor in the subventricular zone (SVZ) in adult brain. OPCs can proliferate, migrate and differentiate into ma-ture oligodendrocytes to repair the injured myelin in white matter, which termed as remyelination (65, 66). However, the naïve remyelination is insufficient to help repair the damaged myelin. The axon-glia unit in the white matter should be considered as integrity when proper treatment was applied for stroke therapy (67).

White matter lesions often correlate with severe phy-

sical and mental disability. White matter lesion volume is positively related with the reduction of fine motor skills (68). In clinical patients, severe white matter lesions are a predictor for poor activities of daily living in the older stroke patients with mild neurological symptoms (69), and large deep white matter lesions in acute ischemic stroke patients, measuring by pretreatment diffusion-weighted MRI, indicate a signal for useless of recanalization in endovascular therapy (70). Meanwhile, subcortical white matter infarcts influence the risk of post-stroke fatigue and predict one year poor outcomes in stroke patients (71). Moreover, white matter changes due to arterial stif-fness and hypoperfusion also lead to pulse pressure and cognitive decline in stroke and transient ischemic stroke patients (72). Some studies have showed that the lesion volume in the white matter is closely related with hos-pital admissions due to hip-fractures and trauma after is-chemic stroke (73). Furthermore, motor skill learning and speech fluency are deteriorated by the white matter injury diffusion in chronic stroke patients (74, 75). Recognition memory impaired after white matter stroke in mice (76). White matter lesions are showed to be an independent pre-dictor of stroke in elder people, but not any other vascu-lar diseases (77). These studies show the important roles of white matter in stroke recovery. Since stroke induced white matter injury is strongly related with the recovery extent of patients, more and more work should not only focus on angiogenesis and neurogenesis, but also on mye-lin protection and remyelination.

Recently, several studies have been focused on how to improve remyelination process. Our previously data showed netrin-1 gene therapy (78) and SDF-1/CXCL12 gene therapy (34) can promote angiogenesis and neuroge-nesis. After that we further found that netrin-1gene therapy (79) and SDF-1/CXCL12 gene therapy (80) promoted re-myelination after ischemic stroke in mice by enhancing the proliferation, migration and differentiation of OPCs, which also improved the animals' behavioral function. A few of stem cell treatment studies have been showed the restoration of the white matter injury in ischemic stroke. Intravenously administration of adipose-derived MSCs was showed the migration and implantation of MSCs in the brain as well as facility of axonal sprouting, remyeli-nation and oligodendrogenesis. Meanwhile, MSC treated animals showed a smaller functional deficit, smaller lesion area, and less cell death (81). Another study also showed that combination treatment ischemic rats with Niaspan and bone marrow stem cells (BMSCs) increased white matter remodeling comparing with BMSCs treatment only (82). Although several pioneer studies have been done to pro-mote the remyelination after stroke, more trials are needed to find the sufficient therapeutic treatments for remyelina-tion after stroke.

Conclusion

Comparing with the lots of studies on promoting an-giogenesis and neurogenesis after ischemic stroke, few studies have been done on enhancing remyelination. As a whole brain after stroke, angiogenesis, neurogenesis and remyelination should be treated the same important in the stroke treatments, with no one left behind. Each of them is indispensable for neurobehavioral function recovery.

Since stroke induced white matter injury deteriorates the neurobehavioral function, attention should also be paid to white matter injury and white matter recovery after stroke. The treatments on how to enhance the remyelination should also be treated as important as promoting angioge-nesis and neurogenesis. Angiogenesis, neurogenesis, and remyelination should be paralleled to each other, when considering stroke recovery treatment.

References

1. Hassan A, and Markus HS. Genetics and ischaemic stroke. Brain 2000; 123 (Pt 9): 1784-812.

2. Rubattu S, Giliberti R, and Volpe M. Etiology and pathophysiology of stroke as a complex trait. American journal of hypertension 2000; 13: 1139-48.

3. Martin RL, Lloyd HG, and Cowan AI. The early events of oxygen and glucose deprivation: setting the scene for neuronal death? Trends Neurosci 1994; 17: 251-7.

4. Frizzell JP. Acute stroke: pathophysiology, diagnosis, and treatment. AACN Clin Issues 2005; 16: 421-40; quiz 597-8.

5. Zivin JA. Acute Stroke Therapy With Tissue Plasminogen Activator

(tPA) Since It Was Approved by the US Food and Drug

Administration (FDA). Annals of neurology 2009; 66: 6-10.

6. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-29.

7. Bliss T, Guzman R, Daadi M, and Steinberg GK. Cell transplantation therapy for stroke. Stroke; a journal of cerebral circulation 2007; 38: 817-26.

8. Moskowitz MA, Lo EH, and Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010; 67: 181-98.

9. Broughton BR, Reutens DC, and Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke; a journal of cerebral circulation 2009; 40: e331-9.

10. Ginet V, Puyal J, Clarke PG, and Truttmann AC. Enhancement of autophagic flux after neonatal cerebral hypoxia-ischemia and its re-gion-specific relationship to apoptotic mechanisms. Am J Pathol 2009;

175: 1962-74.

11. Peng Z, Young B, Baird AE, and Soper SA. Single-pair fluores-cence resonance energy transfer analysis of mRNA transcripts for highly sensitive gene expression profiling in near real time. Analytical chemistry 2013; 85: 7851-58.

12. Peng Z. Single-Molecule Detection of Molecular Beacons Gene-rated from LDR on Thermoplastic Microfluidic Device for Bioanaly-sis. 2012.

13. Liu Y, Tang G, Li Y, Wang Y, Chen X, Gu X, et al. Metformin atte-nuates blood-brain barrier disruption in mice following middle cerebral artery occlusion. J Neuroinflammation 2014; 11: 177.

14. Huang J, Li Y, Tang Y, Tang G, Yang GY, and Wang Y. CXCR4 antagonist AMD3100 protects blood-brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke; a journal of cerebral circulation 2013; 44: 190-7.

15. Schabitz WR, Kruger C, Pitzer C, Weber D, Laage R, Gassler N, et al. A neuroprotective function for the hematopoietic protein granulo-cyte-macrophage colony stimulating factor (GM-CSF). Journal of ce-rebral blood flow and metabolism : official journal of the International

Society of Cerebral Blood Flow and Metabolism 2008; 28: 29-43.

16. Hasselblatt M, Ehrenreich H, and Siren AL. The brain erythropoie-tin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol 2006; 18: 132-8.

17. Schabitz WR, and Schneider A. New targets for established proteins: exploring G-CSF for the treatment of stroke. Trends Pharma-col Sci 2007; 28: 157-61.

18. Spera PA, Ellison JA, Feuerstein GZ, and Barone FC. IL-10 re-duces rat brain injury following focal stroke. Neurosci Lett 1998; 251: 189-92.

19. Chen J, Zhang C, Jiang H, Li Y, Zhang L, Robin A, et al. Ator-vastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Meta-bolism 2005; 25: 281-90.

20. Tagami M, Ikeda K, Nara Y, Fujino H, Kubota A, Numano F, et al. Insulin-like growth factor-1 attenuates apoptosis in hippocampal neurons caused by cerebral ischemia and reperfusion in stroke-prone spontaneously hypertensive rats. Lab Invest 1997; 76: 613-7.

21. Li WL, Cai HH, Wang B, Chen L, Zhou QG, Luo CX, et al. Chro-nic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. Journal of neuroscience research 2009; 87: 112-22.

22. Luo CX, Zhu XJ, Zhou QG, Wang B, Wang W, Cai HH, et al. Re-duced neuronal nitric oxide synthase is involved in ischemia-induced hippocampal neurogenesis by up-regulating inducible nitric oxide syn-thase expression. Journal of neurochemistry 2007; 103: 1872-82.

23. Buhnemann C, Scholz A, Bernreuther C, Malik CY, Braun H, Schachner M, et al. Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke lesions of adult rats. Brain 2006; 129: 3238-48.

24. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, and Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010; 28: 1099-106.

25. Yoo SW, Kim SS, Lee SY, Lee HS, Kim HS, Lee YD, et al. Mesen-chymal stem cells promote proliferation of endogenous neural stem cells and survival of newborn cells in a rat stroke model. Exp Mol Med 2008; 40: 387-97.

26. Fan Y, Shen F, Frenzel T, Zhu W, Ye J, Liu J, et al. Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Annals of neurology 2010; 67: 488-97.

27. Li Q, Tang G, Xue S, He X, Miao P, Li Y, et al. Silica-coated super-paramagnetic iron oxide nanoparticles targeting of EPCs in ischemic brain injury. Biomaterials 2013; 34: 4982-92.

28. Li Y, Ma Y, Wang Y, and Yang G-Y. Endothelial Progenitor Cell Therapy in Stroke. Cellular Therapy for Stroke and CNS Injuries 2015: 125-61.

29. Zhang R, Zhang Z, Wang L, Wang Y, Gousev A, Zhang L, et al. Activated neural stem cells contribute to stroke-induced neurogene-sis and neuroblast migration toward the infarct boundary in adult rats. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2004; 24: 441-8.

30. Tang Y, Wang J, Lin X, Wang L, Shao B, Jin K, et al. Neural stem cell protects aged rat brain from ischemia-reperfusion injury through neurogenesis and angiogenesis. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral

Blood Flow and Metabolism 2014; 34: 1138-47.

31. Li J, Tang Y, Wang Y, Tang R, Jiang W, Yang GY, et al. Neurovas-cular recovery via co-transplanted neural and vascular